Back to search results

Observational Study for Pancreatic Cancer Treatment Selection

This study is looking at how well standard treatments like FOLFIRINOX or Gemcitabine + Nab-paclitaxel work for people with pancreatic cancer that is either resectable (can be removed by surgery) or borderline resectable. Researchers will collect blood and tissue samples from participants to look for "biomarkers" (biological signs in your body). The goal is to see if these biomarkers can help predict which treatment will work best for future patients. You might be able to join if you are 18 or older, have confirmed pancreatic cancer that is resectable or borderline resectable, and have a good performance status (ECOG Performance Status of ≤ 1). The study aims to enroll 100 participants and will track how well treatments work for up to two years.

Study design
This is an observational study, meaning researchers will collect information from 100 participants undergoing standard care. It is not a randomized trial.
What's involved
You would provide blood and archival tumor tissue samples. The study will collect information while you undergo standard neoadjuvant treatment.
Compensation
Not stated in the trial record.
Follow-up
The study will track treatment response for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06320717

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Recruiting
Not specifiedAges 18+Observational
Roswell Park Cancer Institute
~100 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Blood sample

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Retrospective prediction of pCR in resectable patients
Measured over Up to 2 years
+1 more outcome measured

Conditions

Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT06320717

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Good Samaritan University Hospital

    West Islip, New Yorkstudy coordinator listed

    Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christos Fountilas, MD · PRINCIPAL_INVESTIGATOR · Roswell Park Comprehensive Cancer Center

Who to contact

Christos Fountzilas, MD
[email protected]
716-845-2300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have histologically or cytologically confirmed PDAC that is borderline resectable (BR) (Cohort A) OR have histologically or cytologically confirmed PDAC that is resectable (Cohort B) using the National Comprehensive Cancer Network criteria \[35\].
Availability of archival tumor tissue (diagnostic for PDAC) required
Have a documented ECOG Performance Status of ≤ 1
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form (ICF) prior to receiving any study related procedure.

Exclusion

Has received prior systemic treatment (standard of care or experimental) for PDAC
Participant has a concurrent malignancy requiring active treatment during the study.

What this trial measures

  • Retrospective prediction of pCR in resectable patientsUp to 2 years

    Pathologic response is based on the American College of Pathology Criteria. The AI classified treatment is based on the best representative slide analyzed by the Valar Labs AI algorithm for V-FFX (is Folfirinox recommended) and V-GNP (is GEM/NAB-Paclitaxel recommended

  • Retrospective prediction of pCR in borderline resectable patientsUp to 2 years

    Pathologic response is based on the American College of Pathology Criteria. The AI classified treatment is based on the best representative slide analyzed by the Valar Labs AI algorithm for V-FFX (is Folfirinox recommended) and V-GNP (is GEM/NAB-Paclitaxel recommended). Pathologic response is based on the American College of Pathology Criteria. The AI classified treatment is based on the best representative slide analyzed by the Valar Labs AI algorithm for V-FFX (is Folfirinox recommended) and V-GNP (is GEM/NAB-Paclitaxel recommended)